Corient Private Wealth
CRL icon

Corient Private Wealth’s Charles River Laboratories CRL Stock Holding History

Corient Private Wealth’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.02M Sell
17,762
-35,036
-66% -$6.5M ﹤0.01% 1051
2025
Q4 		$7.04M Buy
52,798
+42,336
+405% +$7.68M ﹤0.01% 906
2025
Q3 		$1.64M Sell
10,462
-1,363
-12% -$216K ﹤0.01% 1162
2025
Q2 		$1.79M Buy
11,825
+6,669
+129% +$889K ﹤0.01% 1083
2025
Q1 		$776K Sell
5,156
-2,926
-36% -$491K ﹤0.01% 1390
2024
Q4 		$1.49M Sell
8,082
-3,876
-32% -$747K ﹤0.01% 1124
2024
Q3 		$2.36M Sell
11,958
-328
-3% -$68.2K ﹤0.01% 1025
2024
Q2 		$2.54M Buy
12,286
+2
+0% +$453 ﹤0.01% 929
2024
Q1 		$3.33M Sell
12,284
-1,074
-8% -$256K 0.01% 821
2023
Q4 		$3.16M Buy
13,358
+7,127
+114% +$1.4M 0.01% 829
2023
Q3 		$1.22M Buy
6,231
+2,713
+77% +$557K ﹤0.01% 1123
2023
Q2 		$740K Buy
3,518
+372
+12% +$74K ﹤0.01% 1266
2023
Q1 		$635K Buy
3,146
+316
+11% +$71.6K ﹤0.01% 1280
2022
Q4 		$617K Buy
+2,830
New +$618K ﹤0.01% 1075

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Corient Private Wealth's CRL Position: Q1 2026 in Review

Corient Private Wealth reduced its Charles River Laboratories (CRL) stake by 66% in Q1 2026, selling an estimated $6.5M and leaving 17,762 shares worth $3.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1051.

Corient Private Wealth first reported a position in CRL in Q4 2022 and has held it in 14 quarters since. The position peaked at $7.04M in Q4 2025. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Corient Private Wealth held 17,762 shares of Charles River Laboratories worth $3.02M as of Q1 2026.
  • Corient Private Wealth sold 35,036 Charles River Laboratories shares in Q1 2026, an estimated $6.5M.
  • Charles River Laboratories made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #1051 holding.
  • Corient Private Wealth first reported a position in Charles River Laboratories in Q4 2022 and has held it in 14 quarters since.
  • Corient Private Wealth's Charles River Laboratories position peaked at $7.04M in Q4 2025.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.